The english version of the website of the School of Medicine is under development

Δημοσίευση

Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report.

TitleEffect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report.
Publication TypeJournal Article
Year of Publication2014
AuthorsKargiotis, K., Katsiki N., Athyros V. G., Giouleme O., Patsiaoura K., Katsiki E., Mikhailidis D. P., & Karagiannis A.
JournalCurr Vasc Pharmacol
Volume12
Issue3
Pagination505-11
Date Published2014 May
ISSN1875-6212
KeywordsAdult, Biopsy, Drug Administration Schedule, Female, Fluorobenzenes, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia, Liver, Liver Function Tests, Male, Metabolic Syndrome X, Non-alcoholic Fatty Liver Disease, Prospective Studies, Pyrimidines, Rosuvastatin Calcium, Sulfonamides, Time Factors
Abstract

BACKGROUND: There is no widely accepted treatment for non-alcoholic fatty liver disease (NAFLD) or its advanced form, non-alcoholic steatohepatitis (NASH).METHODS: We administered rosuvastatin (10 mg/day) for 1 year in patients with metabolic syndrome (MetS), NASH on liver biopsy and dyslipidaemia (but without diabetes or arterial hypertension). Patients also received lifestyle advice.RESULTS: We report preliminary results for 6 patients. The second biopsy (at the end of the study) showed complete resolution of NASH in 5 patients, while the 6(th), which had no improvement, developed arterial hypertension and substantial rise in triglyceride levels during the study. We suspect alcohol abuse despite advice to abstain. Serum alanine transaminase (ALT) and aspartate transaminase (AST) activities were reduced by 76 and 61%, respectively (p < 0.001 for both), during treatment, while γ-glutamyl transpeptidase (γ-GT), and alkaline phosphatase (AP) showed smaller non significant reductions. Fasting plasma glucose and glycated haemoglobin (HbA1c) were significantly reduced (p<0.05). Lipid values were totally normalised and liver ultrasonography showed a complete resolution of NASH in 5 patients. Body mass index and waist circumference remained unchanged during the study. Thus, changes in liver pathology and function should be attributed to treatment with rosuvastatin. A substantial limitation of the study is the small number of patients.CONCLUSIONS: These preliminary findings suggest that rosuvastatin could ameliorate NASH within a year of treatment in MetS patients with dyslipidaemia.

Alternate JournalCurr Vasc Pharmacol
PubMed ID24805248

Contact

Secretariat of the School of Medicine
 

Connect

Schoole of Medicince presence in social networks
Follow Us or Connect with us.